Zogenix Inc

Zogenix — Investor Presentation (September 2014)

32 slides from Zogenix's investor presentation, Sep 8, 2014

  1. Slide 1: Overview September 2014

    Overview September 2014 NASDAQ:

  2. Slide 2: Forward Looking Statement

    2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assumin

  3. Slide 3: The Zogenix Opportunity

    3 The Zogenix Opportunity UNIQUE MODEL Combining Medicine and Technology to Provide Differentiated Products That Meet Medical Needs PROVEN EXECUTION 2 FDA Approvals, Successful Commercial Product, Validated DosePro Platform, Strong Pipeline SIGNIFICANT MARKET OPPORTUNITY 1st to Market in Large Oppor

  4. Slide 4: Unique Model: Combining Medicine and Technology

    4 Oral, 12-Hour Extended Release Once Monthly Subcutaneous Injection DosePro® Needle-Free Delivery Platform Unique Model: Combining Medicine and Technology COMMERCIALIZING and DEVELOPING Innovative Products CHRONIC PAIN ANTIPSYCHOTIC INTERNAL/EXTERNAL Hydrocodone Without Acetaminophen Risperidone De

  5. Slide 5: CHRONIC PAIN ANTIPSYCHOTIC CNS 1st to Develop/Market Oral, 12-Hour Extended Release Hydrocodone without Acetaminophen

    5 CHRONIC PAIN ANTIPSYCHOTIC CNS 1st to Develop/Market Oral, 12-Hour Extended Release Hydrocodone without Acetaminophen 1st $16B Market US Market Unpartnered Launch March 2014 Subcutaneous Once-Monthly Antipsychotic 1st $29B+ Market* Worldwide Market Rights Phase 1 *12 months ended March 2014 Retail

  6. Slide 6: SUMAVEL DosePro Transaction

    6 SUMAVEL DosePro® Transaction • Better Call Point Fit • Significant Resources for Education and Marketing • Transfer of New Drug Application • Worldwide Product Rights • Purchase of Finished Goods Inventory • Strengthens Balance Sheet: $89.6M* in Cash, $20M in Milestone Payments • Ownership of Dose

  7. Slide 7: Strong Pipeline

    7 Strong Pipeline PRODUCT/ PROGRAM Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Commercial Status ZOHYDRO® ER ER Hydrocodone Capsules For Chronic Pain  Approved October 25 2013  Launched March 3rd 2014 2 AD Formulations N/A N/A • ADT capsules targeting 1H2015 • ADT tablets targeting Late 2016 RELDAYTM

  8. Slide 8: Oral, Extended Release Hydrocodone

    8 Oral, Extended Release Hydrocodone Acetaminophen-Free Hydrocodone Product FDA Approved October 2013 Launched March 2014 1st 1st

  9. Slide 9: ZOHYDRO ER Progress

    9 ZOHYDRO ER Progress • 10,299 Prescriptions in Second Quarter 2014 • ~21,000 Prescriptions and ~3,400 Prescribers from Launch Through August 29, 2014 • >85% of Prescriptions for ZOHYDRO ER are for the 30 mg Strength or Less, as Anticipated MOMENTUM EDUCATION/ LEGAL • Engaging Local, State and Natio

  10. Slide 10: ZOHYDRO ER

    10 • Multiple Strengths (10-50 mg) • DEA Schedule II Product with Class-Wide REMS • Voluntary Initiatives to Support Appropriate Use • 2 Orange Book Patents with Expiry in Nov 2019 • Orange Book NP Exclusivity Through Oct 2016 • Abuse Deterrent (AD) Formulations in Development that May Also Extend P

  11. Slide 11: Ideal Profile for Chronic Pain Treatment

    11 Ideal Profile for Chronic Pain Treatment ZOHYDRO ER vs. Vicodin CONSISTENT 12 Hour Profile to Prevent Breakthrough Pain LOWER Maximum Concentration LESS Peak to Trough Variation Mean Plasma Concentration ng/ml 0 5 10 15 20 25 30 35 0 4 8 12 16 20 24 28 32 Time (Hours) Zohydro ER 20 mg T0 Vicodin

  12. Slide 12: Responder Graph and Indication Details

    12 p < 0.001 p < 0.001 68% 31% 0 10 20 30 40 50 60 70 80 ≥10 ≥20 ≥30 ≥40 ≥50 ≥60 ≥70 ≥80 ≥90 HC-ER Placebo ZOHYDRO ER is an Opioid Agonist, Extended-Release Oral Formulation of Hydrocodone Without Acetaminophen, for the Management of Pain Severe Enough to Require Daily, Around-the-Clock, Long-Term O

  13. Slide 13: Lower Liver Toxicity

    13 Lower Liver Toxicity 1. Larson AM et al. Acetaminophen-Induced Acute Liver Failure: Results a United States Multicenter, Prospective Study. HEPATOLOGY 2005;42:1364-1372 2. Michna, E, Duh, MS, Korves, C, Dahl, JL. Removal of opioid/acetaminophen comvination prescription pain medications: assessing

  14. Slide 14: The Market Need for Extended Release Hydrocodone

    14 13 Million ER Opioid TRx Annually The Market Need for Extended Release (ER) Hydrocodone Hydrocodone Oxycodone Morphine Oxymorphone Hydromorphone 5.0M 6.6M 1.0M 0.2M ER Products OxyContin Avinza, Kadian, Embeda, MS Contin+ Generic ERs Opana ER (Including Generics) Exalgo ER Sales $2.6B $1.4B $528M

  15. Slide 15: The Medical Need

    15 The Medical Need 47 Million* Patients Take IR HC/APAP Meeting the Need in Opioid Rotation * FDA analysis of IMS Health Total Patient Tracker data for 2011 (presented at Zohydro ER Advisory Committee, December 2012) 1 Proportion of chronic use patients based upon Ingenix Employer Solutions claims

  16. Slide 16: ZOHYDRO ER Illustrative 5% Market Opportunity

    16 2.4 Million Patients 5% Penetration (120,000 Patients) WAC Price per Day of Therapy: $11.83 Gross WAC to Net Selling Price Deductions: 35-45% Days per Month of Therapy: 30 # of TRx per Year: 8 ZOHYDRO ER Illustrative 5% Market Opportunity Approximately $341 Million in Gross Revenue $187 - $222 Mi

  17. Slide 17: Systematic Approach to Responsible Commercialization

    17 Systematic Approach to Responsible Commercialization • Broad, Integrated Educational Resources for Patients, Physicians and Pharmacists EDUCATION • Commercial Activity Focused On Selected Physicians MARKETING • Certification of Zogenix Territory Representatives • Incentive Compensation Based Excl

  18. Slide 18: Multiple Educational Resources for Patients, Prescribers, and Pharmacists

    18 Multiple Educational Resources for Patients, Prescribers, and Pharmacists HCP Kit Patient Toolkit Education and Safe Storage Offers Conversion Guide Healthcare and Provider Websites

  19. Slide 19: Successful Execution: ZOHYDRO ER Targeting a Significant Footprint

    19 Successful Execution: ZOHYDRO ER Targeting a Significant Footprint 20,000 High Decile ER/LA Opioid Prescribers (Top 6 Deciles) of ER Opioid Market 60% Commercial Organization of 190 Employees FOCUS COMMITMENT COMPLIANCE CONTROL Responsibly Building Adoption for Long-Term Success    

  20. Slide 20: Committed to Developing Abuse Deterrent Formulations

    20 Modification of Existing SODAS Formulation with Alkermes • First Step in ADF of ZOHYDRO ER Capsules • Addition of Inert Beads That Form a Viscous Gel When Crushed and Dissolved in Aqueous Solvents • Insufflation and Injection Resistant • Targeting sNDA submission by October 2014; if approved, pot

  21. Slide 21: Once-Monthly Risperidone Subcutaneous Injection

    21 Once-Monthly Risperidone With A Unique PK Profile, Available as a Subcutaneous Injection for Treatment of Schizophrenia 1st Phase 1 Proof of Concept Established

  22. Slide 22: Long Acting Injections: A Highly Attractive Market

    22 • Highly Concentrated U.S. Market with 11,000 Psychiatrists Prescribing Long- Acting Injectable Antipsychotics • Growing U.S. and EU Market for LAI Products • Risperdal Consta, 100mg/Month >$1,200 in U.S. $2.8 Billion Market in U.S.+ Europe in 2013 Long Acting Injections (LAIs): A Highly Attracti

  23. Slide 23: RELDAY Surpasses Current LAI Atypical Antipsychotics

    23 RELDAY Surpasses Current LAI Atypical Antipsychotics (AA) on Multiple Attributes KEY ATTRIBUTES FROM PHYSICIAN RESEARCH RISPERDAL CONSTA (RISPERIDONE) INVEGA SUSTENNA (PALIPERIDONE) ZYPREXA RELPREVV (OLANZAPINE) ABILIFY MAINTENA (ARIPIPRAZOLE) RELDAY (RISPERIDONE) Therapeutic Levels on Day 1 × ×

  24. Slide 24: RELDAY: A Differentiated Product Profile vs. Available LAIs

    24 RELDAY: A Differentiated Product Profile vs. Available LAIs 1% 5% 25% 51% 18% 2% 6% 31% 49% 12% 0 0.2 0.4 0.6 Very Negative Negative Somewhat Negative Neutral Somewhat Positive Positive Very Positive % of Participants Positive Physician Reaction Higher Relative Rating 7 POINT SCALE: 1 = “WORST” A

  25. Slide 25: RELDAY Clinical Program Status

    25 RELDAY Clinical Program Status • Established in the First IND Study • Subjects with Schizophrenia (n=40) • Pharmacokinetics (PK) – Therapeutic Levels within 8 hours of Dosing – First Day Levels Consistent with Comparable Oral Dose – Duration Consistent with Once-monthly Dosing – Dose-Proportional

  26. Slide 26: RELDAY Clinical Study Design

    26 RELDAY Clinical Study Design • Starts in Q1 2015, ends Q3 2015 • Initiate Multiple-Dose PK and Safety Study (Q1 2015) • ROW Partnering With Data (H2 2015) • End of Phase II Meeting (Q3/Q4 2015) • Begin Phase III Trial (H1 2016) OVERVIEW INJECTIONS TIMING NEXT STEPS (Target Dates) • Relday Patient

  27. Slide 27: Financial Highlights

    27 Financial Highlights Q2 2014 Total Revenue (Zohydro ER revenue of $2.4M) $9.2M Market Capitalization (8-6-14 ~139,539,151 Shares) $190M Q2 2014 Cash Balance $81.2M + $8.5M of restricted cash held in escrow Debt (1) $0M Common Stock Outstanding 139,539,151 Fully Diluted Shares (2) 174,449,634 Empl

  28. Slide 28: 2014 Revenue Guidance

    28 2014 Revenue Guidance ZOHYDRO ER Revenue • Continue sell-through rev. recog. methodology for Zohydro ER at least through remainder of 2014 • Expect $240 average net selling price per prescription for the remainder of 2014 • No further net product revenue for SUMAVEL DosePro Contract Manufacturing

  29. Slide 29: 2014 Expense Guidance

    29 2014 Expense Guidance Cost of Goods Sold and Product Gross Margin • Expecting product gross margin of approximately 80% for Zohydro ER, reflecting a manufacturing fee of 15% on Zohydro ER net product revenue, plus internal manufacturing overhead and other costs Cost of contract manufacturing • Co

  30. Slide 30: Experienced Management Team

    30 Experienced Management Team INDUSTRY EXPERIENCE Roger Hawley* Chief Executive Officer 27 Glaxo, GSK, Elan, InterMune Stephen Farr, Ph.D.* President 21 Aradigm, Cardiff University Ann Rhoads Chief Financial Officer 20 Premier, Sprout, DLJ, Bain & Co, Merrill Lynch Bradley Galer, M.D. Chief Medical

  31. Slide 31: Zogenix: Where Medicine Meets Technology

    31 Zogenix: Where Medicine Meets Technology DEVELOPING and COMMERCIALIZING Innovative Products PROVEN EXECUTION RESPONSIBLE COMMERCIALIZATION UNIQUE MODEL INFRASTRUCTURE IN PLACE SIGNIFICANT MARKETS CHRONIC PAIN 1st INTERNAL/EXTERNAL 1st DosePro® Needle-Free Delivery Platform ANTIPSYCHOTIC 1st

  32. Slide 32: LOGENIX® —. EM le

    NASDAQ: ZGNX LOGENIX® —. EM le

Zogenix — Investor Presentation (September 2014) on 6ix